Poniard Pharmaceuticals Inc. reported financial results for the fourth quarter and year ended December 31, 2009. The Company reported a net loss of $13.2 million for the fourth quarter. Ronald A. Martell, Chief Executive Officer of Poniard said "We look forward to finalizing registration strategies in a number of these settings with our clinical advisors and the Food and Drug Administration, while simultaneously evaluating strategic opportunities, including potential partnerships, which we believe will enable us to unlock the full value of picoplatin." The Company will pursue strategic opportunities, including a partnership to help advance the clinical development of picoplatin in multiple indications and two formulations in 2010.

Poniard Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2009. For the quarter, loss from operations was $12,448,000 against $13,357,000 a year ago. Net loss was $13,168,000 against $13,942,000 a year ago. Loss applicable to common shares was $13,293,000 or $0.36 per basic and diluted share against $14,067,000 or $0.41 per basic and diluted share a year ago. For the full year, loss from operations was $42,978,000 against $49,157,000 a year ago. Net loss was $45,715,000 against $48,565,000 a year ago. Loss applicable to common shares was $46,215,000 or $1.31 per basic and diluted share against $49,065,000 or $1.41 per basic and diluted share a year ago.

Poniard Pharmaceuticals, Inc. announced that they will report Q4, 2009 results on 03/08/2010